A detailed history of Buckingham Strategic Partners transactions in Pfizer Inc stock. As of the latest transaction made, Buckingham Strategic Partners holds 102,827 shares of PFE stock, worth $2.75 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
102,827
Previous 92,154 11.58%
Holding current value
$2.75 Million
Previous $2.58 Million 15.4%
% of portfolio
0.07%
Previous 0.07%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.7 - $31.39 $295,642 - $335,025
10,673 Added 11.58%
102,827 $2.98 Million
Q2 2024

Aug 13, 2024

BUY
$25.26 - $29.6 $337,650 - $395,663
13,367 Added 16.97%
92,154 $2.58 Million
Q1 2024

May 15, 2024

BUY
$25.89 - $29.73 $1.18 Million - $1.36 Million
45,667 Added 137.88%
78,787 $2.19 Million
Q4 2023

Feb 14, 2024

SELL
$26.13 - $33.94 $843,659 - $1.1 Million
-32,287 Reduced 49.36%
33,120 $953,000
Q3 2023

Nov 14, 2023

BUY
$32.09 - $37.51 $1.22 Million - $1.42 Million
37,883 Added 137.64%
65,407 $2.17 Million
Q2 2023

Aug 14, 2023

BUY
$36.12 - $41.79 $72,637 - $84,039
2,011 Added 7.88%
27,524 $1.01 Million
Q1 2023

May 15, 2023

SELL
$39.39 - $51.28 $56,485 - $73,535
-1,434 Reduced 5.32%
25,513 $1.04 Million
Q4 2022

Feb 14, 2023

SELL
$41.75 - $54.5 $876,332 - $1.14 Million
-20,990 Reduced 43.79%
26,947 $1.38 Million
Q3 2022

Nov 14, 2022

BUY
$43.76 - $53.42 $832,402 - $1.02 Million
19,022 Added 65.79%
47,937 $2.1 Million
Q2 2022

Aug 12, 2022

BUY
$46.53 - $55.17 $333,806 - $395,789
7,174 Added 33.0%
28,915 $1.52 Million
Q1 2022

May 10, 2022

BUY
$45.75 - $56.69 $994,650 - $1.23 Million
21,741 New
21,741 $1.13 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $150B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Buckingham Strategic Partners Portfolio

Follow Buckingham Strategic Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Partners with notifications on news.